1-(2-(Dimethylamino)ethyl)-1-(4-methoxyphenyl)-3-(4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)urea

ID: ALA3410051

Chembl Id: CHEMBL3410051

PubChem CID: 118732105

Max Phase: Preclinical

Molecular Formula: C25H28N6O2

Molecular Weight: 444.54

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc(N(CCN(C)C)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)cc1

Standard InChI:  InChI=1S/C25H28N6O2/c1-17-15-26-24-22(17)23(27-16-28-24)18-5-7-19(8-6-18)29-25(32)31(14-13-30(2)3)20-9-11-21(33-4)12-10-20/h5-12,15-16H,13-14H2,1-4H3,(H,29,32)(H,26,27,28)

Standard InChI Key:  IFMNGABKTBLAQL-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3410051

    ---

Associated Targets(Human)

LIMK1 Tchem LIM domain kinase 1 (2329 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ROCK2 Tclin Rho-associated protein kinase 2 (6206 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 444.54Molecular Weight (Monoisotopic): 444.2274AlogP: 4.54#Rotatable Bonds: 7
Polar Surface Area: 86.38Molecular Species: NEUTRALHBA: 5HBD: 2
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 11.50CX Basic pKa: 8.25CX LogP: 3.93CX LogD: 3.03
Aromatic Rings: 4Heavy Atoms: 33QED Weighted: 0.44Np Likeness Score: -1.20

References

1. Yin Y, Zheng K, Eid N, Howard S, Jeong JH, Yi F, Guo J, Park CM, Bibian M, Wu W, Hernandez P, Park H, Wu Y, Luo JL, LoGrasso PV, Feng Y..  (2015)  Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,  58  (4): [PMID:25621531] [10.1021/jm501680m]
2. Manetti F..  (2018)  Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials.,  155  [PMID:29908439] [10.1016/j.ejmech.2018.06.016]

Source